SOPHiA GENETICS SA Chief Executive Officer and Director Ross Muken filed a Form 4 on November 9, 2026, disclosing an open-market purchase of 20,000 ordinary shares on November 6, 2026.
Key Highlights
- Transaction: Ross Muken acquired 20,000 ordinary shares of SOPHiA GENETICS SA on November 6, 2026, with transaction code P (purchase).
- Weighted average price: The reported price per share was $6.8594, a weighted average across multiple transactions ranging from $6.70 to $7.08, inclusive.
- Resulting ownership: Following the purchase, Muken directly beneficially owned 680,391 ordinary shares, according to the filing.
- Roles: The filing identifies Muken as both a Director and Chief Executive Officer of the issuer.
- Exchange and ticker: The issuer is listed as NASDAQ:SOPH.
- Signing: The form was signed by Elimara Brunetto as attorney-in-fact for Ross Muken, dated November 9, 2026.
Ross Muken's November 2026 Open-Market Purchase of SOPHiA GENETICS Ordinary Shares
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2026, Ross Muken, Chief Executive Officer and Director of SOPHiA GENETICS SA (NASDAQ:SOPH), purchased 20,000 ordinary shares of the company on November 6, 2026. The transaction is coded "P," indicating an open-market purchase. No derivative securities were reported in Table II of the filing.
The filing discloses that the shares were acquired at a weighted average price of $6.8594 per share. As noted in the filing's footnote, the purchase was made across multiple transactions at prices ranging from $6.70 to $7.08, inclusive. The filing states that Muken "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
Following the reported transaction, Muken's direct beneficial ownership of ordinary shares stands at 680,391, as reported in the filing. The Form 4 was filed by one reporting person and was signed by Elimara Brunetto as attorney-in-fact for Ross Muken on November 9, 2026. No indication is given in the filing that the transaction was made pursuant to a Rule 10b5-1(c) plan.
What Was Disclosed
Ross Muken, CEO and Director of SOPHiA GENETICS SA, disclosed a purchase of 20,000 ordinary shares on November 6, 2026, at a weighted average price of $6.8594, bringing his direct beneficial ownership to 680,391 shares.




Please wait processing your request...